Department of General Medicine, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.
Department of Infectious Diseases, Jingzhou First People's Hospital, Jingzhou, China.
Front Immunol. 2024 Aug 16;15:1420205. doi: 10.3389/fimmu.2024.1420205. eCollection 2024.
Natural Killer (NK) cells play a crucial role as effector cells within the tumor immune microenvironment, capable of identifying and eliminating tumor cells through the expression of diverse activating and inhibitory receptors that recognize tumor-related ligands. Therefore, harnessing NK cells for therapeutic purposes represents a significant adjunct to T cell-based tumor immunotherapy strategies. Presently, NK cell-based tumor immunotherapy strategies encompass various approaches, including adoptive NK cell therapy, cytokine therapy, antibody-based NK cell therapy (enhancing ADCC mediated by NK cells, NK cell engagers, immune checkpoint blockade therapy) and the utilization of nanoparticles and small molecules to modulate NK cell anti-tumor functionality. This article presents a comprehensive overview of the latest advances in NK cell-based anti-tumor immunotherapy, with the aim of offering insights and methodologies for the clinical treatment of cancer patients.
自然杀伤 (NK) 细胞作为肿瘤免疫微环境中的效应细胞,发挥着至关重要的作用,它们通过表达多种识别肿瘤相关配体的激活和抑制受体来识别和消除肿瘤细胞。因此,利用 NK 细胞进行治疗是 T 细胞为基础的肿瘤免疫治疗策略的重要补充。目前,基于 NK 细胞的肿瘤免疫治疗策略包括多种方法,包括过继性 NK 细胞治疗、细胞因子治疗、基于抗体的 NK 细胞治疗(增强 NK 细胞介导的 ADCC、NK 细胞衔接子、免疫检查点阻断治疗)以及利用纳米颗粒和小分子来调节 NK 细胞的抗肿瘤功能。本文全面概述了基于 NK 细胞的抗肿瘤免疫治疗的最新进展,旨在为癌症患者的临床治疗提供见解和方法。
Front Immunol. 2024
Front Immunol. 2020-6-16
Front Immunol. 2021
Semin Immunol. 2019-5-10
Trends Mol Med. 2017-11-10
Front Immunol. 2020-2-19
Nat Rev Clin Oncol. 2021-2
Front Pharmacol. 2025-6-11
Cell Commun Signal. 2024-10-23
Signal Transduct Target Ther. 2023-3-7
Mol Cancer. 2023-2-16
Cancer Commun (Lond). 2023-2
Cancers (Basel). 2022-9-2
Cell Mol Life Sci. 2022-9-6
Nat Rev Cancer. 2022-10
Nat Rev Immunol. 2023-2